EpiEndo Pharmaceuticals has announced the recent appointments of Professor Bartolome Celli and Professor Fernando J. Martinez to its Scientific Advisory Board.

EpiEndo Pharmaceuticals is pleased to be celebrating its 10-year anniversary today.

REYKJAVIK, ICELAND – 2 November 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has initiated a healthy volunteer drug-drug interaction (DDI) clinical trial for lead compound, EP395.

REYKJAVIK, ICELAND – 23 October 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has completed its proof of pharmacology study for lead asset EP395 in healthy volunteers.

REYKJAVIK, ICELAND – 23 October 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has completed its proof of pharmacology study for lead asset EP395 in healthy volunteers.

REYKJAVIK, ICELAND - 23 August 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic airway diseases, has contributed to a chapter in a key medical textbook, published this month.

REYKJAVIK, ICELAND - 16 August 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic airway diseases, will have data presented in three abstracts at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.

EpiEndo Pharmaceuticals announces that CEO, Maria Bech, and CFO, Stefán Pétursson, will be attending the BIO International Convention from June 5-8 at the Boston Convention & Exhibition Center in Boston, Massachusetts.

EpiEndo Pharmaceuticals has appointed Dr Kate Hanrott as Director of Clinical Operations and Sciences, with immediate effect.